Alnylam Pharmaceuticals, Inc. (ALNY) vs Quest Diagnostics Incorporated (DGX)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Quest Diagnostics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 4, 2026. Differences are shown without an overall score or investment verdict.
ALNY
Alnylam Pharmaceuticals, Inc.
$219.72HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
DGX
Quest Diagnostics Incorporated
$233.24HealthcareDelayed quote: Oct 2, 2026, 3:59 PM EDT
Total return — ALNY vs DGX
growth of $100 · dividends reinvested · last 10yALNY +222.0% (+12.4%/yr)DGX +237.5% (+12.9%/yr)DGX compounded faster over this window
ALNY DGX
ALNY vs DGX: by the numbers
- •ALNY is the larger company ($29.40B vs $25.74B market cap).
- •DGX trades at the lower trailing earnings multiple (24.76 vs 37.11 P/E), one valuation lens rather than an overall verdict.
- •ALNY converts more revenue to profit (16.82% vs 9.19% net margin).
- •ALNY grew revenue faster over the past five years (47.53% vs 0.89% CAGR).
- •DGX pays a dividend (1.08% yield), while ALNY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | ALNY | DGX |
|---|---|---|
| P/E ratio | 37.11 | 24.76 |
| Forward P/E | 32.95 | 20.84 |
| P/S ratio | 6.12 | 2.23 |
| P/B ratio | 21.71 | 3.43 |
| EV / EBITDA | 27.47 | 15.77 |
| FCF yield | 1.85% | 4.74% |
Profitability
| Metric | ALNY | DGX |
|---|---|---|
| Gross margin | 79.72% | 33.15% |
| Operating margin | 20.81% | 14.14% |
| Net margin | 16.82% | 9.19% |
| ROE | 59.67% | 14.13% |
| ROIC | 24.71% | 8.25% |
Dividends
| Metric | ALNY | DGX |
|---|---|---|
| Dividend yield | N/A | 1.08% |
| Payout ratio | N/A | 26.75% |
Growth (annualized)
| Metric | ALNY | DGX |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 0.89% |
| EPS CAGR (5Y) | N/A | -3.65% |
| FCF CAGR (5Y) | N/A | -10.89% |
| Total return CAGR (5Y) | 2.66% | 12.51% |
Frequently asked
- Which has the lower trailing P/E, ALNY or DGX?
- DGX has the lower trailing P/E: ALNY trades at 37.11 and DGX at 24.76. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ALNY or DGX?
- Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus DGX at 0.89%.
- Does ALNY or DGX pay a bigger dividend?
- DGX pays a dividend (1.08% yield), while ALNY has no payments in the available dividend history.
- Is ALNY or DGX more profitable?
- ALNY runs the higher net margin — ALNY at 16.82% versus DGX at 9.19%.
- How have ALNY and DGX total returns compared?
- Over the past 10 years, ALNY delivered 12.47% and DGX delivered 12.87% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioQuest Diagnostics P/E ratioQuest Diagnostics dividend yieldAlnylam Pharmaceuticals ROEQuest Diagnostics ROEAlnylam Pharmaceuticals operating marginQuest Diagnostics operating marginAlnylam Pharmaceuticals revenue growthQuest Diagnostics revenue growthAlnylam Pharmaceuticals free cash flowQuest Diagnostics free cash flow
Alnylam Pharmaceuticals & Quest Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 4, 2026.